Cargando…
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment
BACKGROUND: Sarcopenia, defined as the loss of skeletal muscle mass (MM), physical performance, and strength, has been associated with poor clinical outcomes in hepatocellular carcinoma (HCC) patients treated with several therapies. As systemic therapies, including molecular targeted agents, have a...
Autores principales: | Yamasaki, Takahiro, Saeki, Issei, Yamauchi, Yurika, Matsumoto, Toshihiko, Suehiro, Yutaka, Kawaoka, Tomokazu, Uchikawa, Shinsuke, Hiramatsu, Akira, Aikata, Hiroshi, Kobayashi, Kazufumi, Kondo, Takayuki, Ogasawara, Sadahisa, Chiba, Tetsuhiro, Takami, Taro, Chayama, Kazuaki, Kato, Naoya, Sakaida, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294968/ https://www.ncbi.nlm.nih.gov/pubmed/35978601 http://dx.doi.org/10.1159/000522389 |
Ejemplares similares
-
Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
por: Saeki, Issei, et al.
Publicado: (2021) -
Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2023) -
Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
por: Ohya, Kazuki, et al.
Publicado: (2019) -
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016) -
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2019)